Literature DB >> 9422782

Structural elements of PC2 required for interaction with its helper protein 7B2.

X Zhu1, L Muller, R E Mains, I Lindberg.   

Abstract

The structures of the eukaryotic subtilisin protease family members can be divided into four distinct domains as follows: the proregion, the catalytic domain, the P domain, and the carboxyl-terminal region. Although these enzymes are evolutionarily related, only prohormone convertase 2 (PC2) requires 7B2 for activation. To examine the potential contribution of each domain of PC2 to PC2-7B2 interactions, we performed sequential deletions, site-directed mutagenesis, and domain swapping to replace individual domains or particular amino acids of pro-PC2 with the corresponding segments/amino acids of pro-PC1. These chimeras and mutant enzyme molecules were then expressed in AtT-20 cells and analyzed for 7B2 binding, maturation ability, and enzymatic activity. The results revealed that 1) the PC2 proregion is required but is not sufficient to confer 7B2 binding; 2) the P domain is required for the stabilization of PC2 structure and is not exchangeable with the P domain of PC1; and 3) the carboxyl-terminal domain is not involved in 7B2 binding. Site-directed mutagenesis of pro-PC2 further showed that a single residue replacement in the catalytic domain, Tyr-194 --> Asp, prevented pro-PC2 from binding 7B2 and blocked activation. This residue is present within a loop rich in aromatic amino acids which appears to be on the surface of the molecule as extrapolated from the crystal structure of subtilisin. This loop may represent the primary recognition site for 7B2 within the catalytic domain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9422782     DOI: 10.1074/jbc.273.2.1158

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Inhibition of prohormone convertases PC1/3 and PC2 by 2,5-dideoxystreptamine derivatives.

Authors:  Mirella Vivoli; Thomas R Caulfield; Karina Martínez-Mayorga; Alan T Johnson; Guan-Sheng Jiao; Iris Lindberg
Journal:  Mol Pharmacol       Date:  2011-12-14       Impact factor: 4.436

Review 2.  Neuroendocrine secretory protein 7B2: structure, expression and functions.

Authors:  M Mbikay; N G Seidah; M Chrétien
Journal:  Biochem J       Date:  2001-07-15       Impact factor: 3.857

3.  7B2 prevents unfolding and aggregation of prohormone convertase 2.

Authors:  Sang-Nam Lee; Iris Lindberg
Journal:  Endocrinology       Date:  2008-05-08       Impact factor: 4.736

4.  Structural organization of precursors of thermolysin-like proteinases.

Authors:  Ilya V Demidyuk; Eugene V Gasanov; Dina R Safina; Sergey V Kostrov
Journal:  Protein J       Date:  2008-09       Impact factor: 2.371

5.  Proprotein convertase subtilisin/kexin type 7 (PCSK7) is essential for the zebrafish development and bioavailability of transforming growth factor β1a (TGFβ1a).

Authors:  Hannu Turpeinen; Anna Oksanen; Virpi Kivinen; Sampo Kukkurainen; Annemari Uusimäki; Mika Rämet; Mataleena Parikka; Vesa P Hytönen; Matti Nykter; Marko Pesu
Journal:  J Biol Chem       Date:  2013-10-31       Impact factor: 5.157

6.  A model for the structure of the P domains in the subtilisin-like prohormone convertases.

Authors:  G M Lipkind; A Zhou; D F Steiner
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

Review 7.  Neuroregulation of ProTRH biosynthesis and processing.

Authors:  E A Nillni
Journal:  Endocrine       Date:  1999-06       Impact factor: 3.633

8.  Mutational analysis of predicted interactions between the catalytic and P domains of prohormone convertase 3 (PC3/PC1).

Authors:  Kazuya Ueda; Gregory M Lipkind; An Zhou; Xiaorong Zhu; Andrey Kuznetsov; Louis Philipson; Paul Gardner; Chunling Zhang; Donald F Steiner
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-29       Impact factor: 11.205

9.  The neuroendocrine protein 7B2 is intrinsically disordered.

Authors:  Indrani Dasgupta; Laura Sanglas; Jan J Enghild; Iris Lindberg
Journal:  Biochemistry       Date:  2012-09-14       Impact factor: 3.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.